- Home
- KC vs NUVB Comparison
KC vs NUVB Comparison
Compare KC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KC | NUVB |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.9B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | KC | NUVB |
|---|---|---|
| Price | $10.88 | $8.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $15.83 | $10.63 |
| AVG Volume (30 Days) | 1.7M | ★ 10.3M |
| Earning Date | 11-19-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,268,313,014.00 | $26,748,000.00 |
| Revenue This Year | $25.92 | $609.55 |
| Revenue Next Year | $17.44 | $197.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 24.11 | ★ 1137.19 |
| 52 Week Low | $8.06 | $1.54 |
| 52 Week High | $22.26 | $8.95 |
Technical Indicators
Market Signals| Indicator | KC | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 34.51 | 68.18 |
| Support Level | $11.15 | $7.80 |
| Resistance Level | $11.77 | $8.95 |
| Average True Range (ATR) | 0.43 | 0.50 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 4.15 | 67.08 |
Price Performance
Historical ComparisonAbout KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.